Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression

We would like to thank the participating investigators, our collaborators at Syneos Health and our colleagues at the Massachusetts General Hospital (MGH) Clinical Trials Network and Institute, whose contribution was critical to controlling the placebo response.

ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study

About the Phase 2 CLARITY Study
The study was conducted in collaboration with the MGH Clinical Trials Network & Institute (CTNI) and randomized 207 adult patients with a confirmed inadequate response to existing first-line selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) therapy for MDD across 27 U.S. clinical research centers.